» Articles » PMID: 17364080

The Use of Biological Agents in the Treatment of Rheumatoid Arthritis

Overview
Specialty General Medicine
Date 2007 Mar 17
PMID 17364080
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis is a common and potentially devastating condition which did not have good treatment options until recently. Pharmacological treatment should not just comprise antiinflammatory agents and corticosteroids. The current therapeutic approach is to start a disease modifying agent early in the illness to prevent eventual joint damage. Older disease modifying anti-rheumatic drugs (DMARDs) include methotrexate, sulphasalazine and hydroxychloroquine. Newer ones such as leflunomide and cyclosporine are also used. A recent advance in the management of rheumatoid arthritis is the use of biological agents which block certain key molecules involved in the pathogenesis of the illness. They include tumour necrosis factor (TNF)- blocking agents such as infliximab, etanercept and adalimumab, the anti-CD 20 agent rituximab and CTLA-4 Ig abatacept. Other agents which are in development include anti-IL6 tocilizumab, anti-CD22 and anti-lymphostat B. In this review, the efficacy and side effects of these agents, their impact on current clinical practice and future trends are discussed.

Citing Articles

Nano-platform Strategies of Herbal Components for the Management of Rheumatoid Arthritis: A Review on the Battle for Next-Generation Formulations.

Prabha J, Kumar M, Kumar D, Chopra S, Bhatia A Curr Drug Deliv. 2023; 21(8):1082-1105.

PMID: 37622715 DOI: 10.2174/1567201821666230825102748.


Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future.

Frazzini S, Riva F, Amadori M Vet Sci. 2021; 8(6).

PMID: 34208413 PMC: 8231284. DOI: 10.3390/vetsci8060109.


Soluble CD83 Triggers Resolution of Arthritis and Sustained Inflammation Control in IDO Dependent Manner.

Royzman D, Andreev D, Stich L, Rauh M, Bauerle T, Ellmann S Front Immunol. 2019; 10:633.

PMID: 31001257 PMC: 6455294. DOI: 10.3389/fimmu.2019.00633.


Early barriers to neonatal porcine islet engraftment in a dual transplant model.

Samy K, Davis R, Gao Q, Martin B, Song M, Cano J Am J Transplant. 2017; 18(4):998-1006.

PMID: 29178588 PMC: 5878697. DOI: 10.1111/ajt.14601.


Dual islet transplantation modeling of the instant blood-mediated inflammatory reaction.

Martin B, Samy K, Lowe M, Thompson P, Cano J, Farris A Am J Transplant. 2015; 15(5):1241-52.

PMID: 25702898 PMC: 4631614. DOI: 10.1111/ajt.13098.